Miss Michelle Lazenby
(hi/ei)
BSc (Hons), MPhil, MSc
Timau a rolau for Michelle Lazenby
Cynorthwy-ydd Ymchwil
Cyhoeddiad
2024
- Halilovic, M. et al. 2024. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.. Leukemia 38, pp. 2561-2572. (10.1038/s41375-024-02405-5)
2020
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191(2), pp. 231-242. (10.1111/bjh.16665)
2019
- Lazenby, M. 2019. Characterisation of extracellular vesicles from the microenvironment in high risk acute myeloid leukaemia. MPhil Thesis, Cardiff University.
2015
- Lazenby, M., Hills, R., Burnett, A. K. and Zabkiewicz, J. 2015. The HSP90 inhibitor ganetespib: a potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39(6), pp. 617-624. (10.1016/j.leukres.2015.03.016)
- Ostronoff, F. et al. 2015. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council report. Journal of Clinical Oncology 33(10), pp. 1157-1164. (10.1200/JCO.2014.58.0571)
2014
- Lazenby, M., Gilkes, A., Marrin, C., Evans, A., Hills, R. K. and Burnett, A. K. 2014. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28, pp. 1953-1959. (10.1038/leu.2014.90)
2013
- Walsby, E. J., Lazenby, M., Pepper, C. J., Knapper, S. and Burnett, A. K. 2013. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology 161(1), pp. 57-67. (10.1111/bjh.12215)
2011
- Walsby, E. J., Lazenby, M., Pepper, C. J. and Burnett, A. K. 2011. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 25(3), pp. 411-419. (10.1038/leu.2010.290)
2008
- Gale, R. et al. 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112(11), pp. 207-207.
Erthyglau
- Halilovic, M. et al. 2024. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.. Leukemia 38, pp. 2561-2572. (10.1038/s41375-024-02405-5)
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191(2), pp. 231-242. (10.1111/bjh.16665)
- Lazenby, M., Hills, R., Burnett, A. K. and Zabkiewicz, J. 2015. The HSP90 inhibitor ganetespib: a potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39(6), pp. 617-624. (10.1016/j.leukres.2015.03.016)
- Ostronoff, F. et al. 2015. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council report. Journal of Clinical Oncology 33(10), pp. 1157-1164. (10.1200/JCO.2014.58.0571)
- Lazenby, M., Gilkes, A., Marrin, C., Evans, A., Hills, R. K. and Burnett, A. K. 2014. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28, pp. 1953-1959. (10.1038/leu.2014.90)
- Walsby, E. J., Lazenby, M., Pepper, C. J., Knapper, S. and Burnett, A. K. 2013. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology 161(1), pp. 57-67. (10.1111/bjh.12215)
- Walsby, E. J., Lazenby, M., Pepper, C. J. and Burnett, A. K. 2011. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 25(3), pp. 411-419. (10.1038/leu.2010.290)
- Gale, R. et al. 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112(11), pp. 207-207.
Gosodiad
- Lazenby, M. 2019. Characterisation of extracellular vesicles from the microenvironment in high risk acute myeloid leukaemia. MPhil Thesis, Cardiff University.